摘要
目的观察哮喘伴过敏性鼻炎(AR)儿童服用孟鲁司特(顺尔宁)后对鼻炎症状的影响。方法选择轻度持续性哮喘患儿50例,分为Ⅰ组25例(伴AR20例,占80.00%)和Ⅱ组25例(伴AR19例,占76.00%)治疗。在为期12周的研究中,Ⅰ组患儿睡前口服孟鲁司特4mg,Ⅱ组患儿雾化吸入布地奈德500μg,均为每天1次,且每天记录鼻炎症状(鼻塞、流涕、喷嚏、鼻痒)和眼部症状(流泪、眼痒、眼部红肿)并评分。结果服用孟鲁司特后第4周,患儿的鼻炎症状和眼部症状明显改善,各评分值与入院前比较差异均有显著性(P<0.05),随着治疗时间的延长,改善程度继续提高。布地奈德组患儿吸入药物后第4周,鼻炎症状和眼部症状也有所减少,但差异无显著性(P>0.05)。两组间眼部症状改善情况比较差异有显著性(P<0.05)。结论孟鲁司特可显著减少轻中度哮喘伴AR儿童的鼻炎和眼部症状,是治疗哮喘伴过敏性鼻炎的有效药物。
Objective To observe the effect of montelukast in the treatment of children with asthma and allergic rhinitis(AR).Methods Fifty children cases with mild and medium persistent asthma and AR were divided into montelukast group(groupⅠ,25 cases,20 cases com-plicated by AR,80%) and budesonide group(groupⅡ,25 cases,19 cases complicated by AR,76%).The patients in monteukast group took orally montelukast 4 mg before going to bed once daily and ones in budesonide group inhaled budesonide 500 μg once daily.To record rhinitis symptoms(nasal obstruction,runny nose,sneezing,nasal itching) and eyes symptoms(lacrimation,eyes itching,eyes redness) and rated the scores according to the rating scales.Results The symptoms of rhinitis and eyes were apparently alleviated after four-week treatment in montelukast group(P 〈0.05) and continuously eased along with the drug being taken.However,these symptoms were eased but not apparent(P 〈0.05) in budesonide group.The ease of the symptoms in montelukast group was better than that in budesonide group(P〉 0.05).Conclusion Montelukast can alleviate the symptoms of rhinitis and eyes in children with mild and medium persistent asthma and allergic rhinitis,which is an effective drug to treat asthma complicated by allergic rhinitis.
出处
《中国药业》
CAS
2010年第19期66-67,共2页
China Pharmaceuticals